Results 241 to 250 of about 436,571 (380)

Glucocorticoid Receptor Activation Reprograms NK Cells to Drive AREG‐Mediated Immunosuppression: A Pan‐Cancer Role for AREG

Advanced Science, EarlyView.
Natural killer cells, central to anti‐tumor defense, undergo unexpected reprogramming within the tumor microenvironment. Instead of producing IFN‐γ and TNF‐α, they elevate amphiregulin, a tumor‐promoting factor. This shift is linked to glucocorticoid receptor activity and prostaglandin signaling.
Qin Wei, Guirong Liang, Rui zeng, Yuancheng Li, Anlan Hong, Hongsheng Wang, Suying Feng, Yan Wang, Yetao Wang   +8 more
wiley   +1 more source

Mechanisms and etiology of male health disorders: hormones, cancer, and fertility. [PDF]

Cell Commun Signal
Cordani M, Ambrosini G, Dando I, González-Menéndez P.   +3 more
europepmc   +1 more source

Antigen processing in vivo and the elicitation of primary CTL responses. [PDF]

, 1995
Nicholas P. Restifo, Igor Bačík, Kari R. Irvine, Jonathan W. Yewdell, Brian J. McCabe, Ronald Anderson, Laurence C. Eisenlohr, Steven A. Rosenberg, Jack R. Bennink   +8 more
openalex   +1 more source

Bimetallic Nanozyme Amplifier for Synergistic Ferroptosis‐Cuproptosis and Metabolic Reprogramming to Reshape Immunosuppressive Tumor Microenvironment

Advanced Science, EarlyView.
The Bimetallic Nanozyme Amplifier (PEG@AuCZ@CC) to maximize hydrogen peroxide production and reprogram tumor metabolism from glycolysis to oxidative phosphorylation. This shift enhances ferroptotic/cuproptotic signaling cascades and creates a glucose‐enriched but lactate‐depleted tumor microenvironment (TME), effectively overcoming immune tolerance in ...
Jianzhang Luo, Kunzhao Huang, Xiaoyuan Yi, Pei Lu, Huaying Xie, Wen Li, Qingyu Zeng, Feifei He, Duo Wang, Liyan Wang   +9 more
wiley   +1 more source

Nanomedicine targeting the PD-1/PD-L1 axis in autoimmune diseases: breaking conventional barriers to restore immune tolerance. [PDF]

J Nanobiotechnology
Xiang G, Cui Y, Wang P, Feng Y, Zhang C, Lou J, Zhou X.   +6 more
europepmc   +1 more source

Characterization of the Peptide Binding Motif of a Rhesus MHC Class I Molecule (Mamu-A*01) That Binds an Immunodominant CTL Epitope from Simian Immunodeficiency Virus [PDF]

, 1998
Todd M. Allen, John Sidney, Marie‐France del Guercio, Rhona L. Glickman, Gary L. Lensmeyer, Donald A. Wiebe, Robert DeMars, C. David Pauza, R. Paul Johnson, Alessandro Sette, David I. Watkins   +10 more
openalex   +1 more source

Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection

Journal of Virology, 2011
V. V. Ganusov, N. Goonetilleke, Michael K P Liu, G. Ferrari, G. Shaw, A. McMichael, P. Borrow, B. Korber, A. Perelson   +8 more
semanticscholar   +1 more source

Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy

Advanced Science, EarlyView.
Strategies for TME‐responsive Nanomaterials to Potentiate Cancer Immunotherapy. Abstract Immunotherapy has emerged as a transformative paradigm in oncology, yet its clinical efficacy remains constrained by the immunosuppressive tumor microenvironment and inadequate spatiotemporal control of existing modalities, resulting in suboptimal patient response ...
Qianqian Huang, Fan Tong, Jiantao Chen, Muzaffar Kayumov, Yue Lv, Yajun Shi, Bengui Ye, Huile Gao   +7 more
wiley   +1 more source

Enhancing anti-tumor immunity by targeting BATF and the STAT1/PD-L1 pathway in cervical carcinoma. [PDF]

Cell Mol Life Sci
Peng X, Zhu Y, Han Y, Cai C.
europepmc   +1 more source

Identification of New HER2/neu-Derived Peptide Epitopes That Can Elicit Specific CTL Against Autologous and Allogeneic Carcinomas and Melanomas [PDF]

, 1999
Rongcun Yang, Flavio Salazar‐Onfray, Jehad Charo, Karl‐Johan Malmberg, Kristina Evrin, Hubert Maes, Koji Kono, Christina Hising, Max Petersson, Olle Larsson, Lan Li, Ettore Appella, Alessandro Sette, Esteban Celis, Rolf Kiessling   +14 more
openalex   +1 more source